【摘要】：目的:探討祛痰活血顆粒治療非酒精性脂肪性肝病(NAFLD)大鼠的作用,并探討其相關(guān)的作用機(jī)制。方法:40只SD大鼠隨機(jī)分成正常組(6只),模型組(34只);除正常組外,采用高脂飲食誘導(dǎo)的方法誘導(dǎo)NAFLD大鼠模型,確認(rèn)造模成功后,將剩余模型組(30只)隨機(jī)分為5組,每組6只,分別為模型組,祛痰活血顆粒高、中、低劑量組(10,5,2.5 g·kg~(-1)),SB203580組(3 mg·kg~(-1)),分別予以灌胃祛痰活血顆粒及腹腔注射p38MAPK抑制劑SB203580,連續(xù)干預(yù)4周。蘇木素-伊紅(HE)及油紅O染色觀察肝臟病理變化;試劑盒測(cè)定血清甘油三酯(TG),總膽固醇(TC),天門(mén)冬氨酸氨基轉(zhuǎn)移酶(AST),丙氨酸氨基轉(zhuǎn)移酶(ALT),肝臟TG;實(shí)時(shí)熒光定量PCR(Real-time PCR)檢測(cè)脂肪組織水通道蛋白7(AQP7)及p38分裂原激活的蛋白激酶(p38MAPK)mRNA表達(dá),酶聯(lián)免疫吸附測(cè)定(ELISA)法檢測(cè)肝臟游離脂肪酸(FFA),脂肪組織AQP7和磷酸化p38MAPK(p-p38MAPK)的表達(dá)。結(jié)果:與正常組比較,模型組大鼠肝臟脂肪變性明顯,血清TG,TC,AST,ALT和肝臟TG,FFA明顯升高,脂肪組織中AQP7 mRNA及AQP7含量表達(dá)降低,p38MAPK mRNA及p-p38MAPK含量升高(P0.05);與模型組比較,祛痰活血顆粒和SB203580可減輕NAFLD大鼠肝臟脂肪變性程度;明顯降低NAFLD大鼠的血清TG,TC,AST,ALT,肝臟TG,FFA(P0.05);各中藥組和SB203580組大鼠脂肪組織AQP7 mRNA和AQP7含量表達(dá)明顯升高,p38MAPK mRNA和pp38MAPK含量明顯降低(P0.05)。結(jié)論:祛痰活血顆粒能減輕或者逆轉(zhuǎn)肝臟的脂肪變性,其機(jī)制可能與抑制脂肪組織p38MAPK活化、上調(diào)AQP7表達(dá),增加甘油入血代謝,減少進(jìn)入肝臟的FFA,從而降低肝臟TG蓄積有關(guān)。
[Abstract]:Objective: to investigate the effect of Quphan Huoxue granule on (NAFLD) rats with non alcoholic fatty liver disease and its related mechanism. Methods 40 Sprague-Dawley rats were randomly divided into normal group (n = 6), model group (n = 34), NAFLD rat model induced by high-fat diet, and the remaining model group (n = 30) were randomly divided into 5 groups, 6 rats in each group. The model group was the model group with high and middle dose of expelling phlegm and activating blood granule, and the low dose group (10 ~ 5U 2.5 g kg ~ (-1) with SB203580 (3 mg kg ~ (-1),) was given by gavage of Quphan Huoxue granule and intraperitoneal injection of p38MAPK inhibitor SB203580 for 4 weeks. The pathological changes of liver were observed by hematoxylin eosin (HE) and oil red O staining. Serum triglyceride (TG), total cholesterol (TC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), liver TGs, real-time quantitative PCR (Real-time PCR) detection of adipose tissue aquaporin 7 (AQP7) and p38 mitogen-activated protein kinase (p38MAPK) mRNA were detected. The expression of AQP7 and phosphorylated p38MAPK (p-p38MAPK) in adipose tissue of liver free fatty acid (FFA),) was detected by enzyme linked immunosorbent assay (ELISA). Results: compared with the normal group, the hepatic steatosis of the model group was significantly higher, the serum TGG tctastit and liver TGP FFA were significantly increased, and the expression of AQP7 mRNA and AQP7 in the adipose tissue decreased significantly (P0.05), and compared with the model group, the expression of p38 MAPK mRNA and p-p38MAPK increased significantly (P0.05), and compared with the model group, the expression of AQP7 and AQP7 mRNA in the adipose tissue decreased significantly (P0.05). Quphan Huoxue granule and SB203580 could reduce the degree of hepatic steatosis in NAFLD rats; significantly reduce the serum TGG TCCA alt and liver TGN FFA in NAFLD rats (P0.05); the expression of AQP7 mRNA and AQP7 in adipose tissue of rats in Chinese medicine group and SB203580 group were significantly increased (P0.05). 3. The expression of AQP7 mRNA and AQP7 in adipose tissue of rats in each Chinese medicine group and SB203580 group were significantly increased (P0.05). Conclusion: Quphan Huoxue granule can attenuate or reverse fatty degeneration of liver, and its mechanism may be related to inhibition of p38MAPK activation in adipose tissue, upregulation of AQP7 expression, increase of blood metabolism of glycerol, decrease of FFAs entering into liver and decrease of accumulation of TG in liver.
【作者單位】： 西南醫(yī)科大學(xué)附屬中醫(yī)醫(yī)院;
【基金】：四川省教育廳2014年度理科重點(diǎn)項(xiàng)目(14ZA0144) 四川省教育廳2015年度理科一般項(xiàng)目(15ZB0156) 瀘州市科技局2016年度項(xiàng)目[2016-R-70(23/24)]
【分類號(hào)】：R285.5;R-332

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李曉博,侯新國(guó),陳麗;脂肪組織腎素-血管緊張素系統(tǒng)研究進(jìn)展[J];國(guó)外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);2004年03期

2 李青;馬鈺;;脂肪組織功能新發(fā)現(xiàn)[J];中華病理學(xué)雜志;2006年06期

3 周立紅;張鐵梅;;脂肪組織生物學(xué)功能的研究進(jìn)展[J];國(guó)外醫(yī)學(xué)(老年醫(yī)學(xué)分冊(cè));2006年02期

4 樊榮;臧益民;;脂肪組織的功與過(guò)評(píng)述[J];心臟雜志;2008年03期

5 梁忠泉;袁昌隆;張寶賀;;脂肪組織的制片技巧[J];中國(guó)療養(yǎng)醫(yī)學(xué);2009年06期

6 劉若冰;魏麗;;脂肪組織的內(nèi)分泌功能研究進(jìn)展[J];求醫(yī)問(wèn)藥(下半月);2013年03期

7 丁明修;脂肪組織病理制片研究[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;1991年02期

8 韓北;;并非所有的脂肪都一樣[J];心血管病防治知識(shí);2009年01期

9 吳秀英;運(yùn)動(dòng)中的是非題測(cè)試[J];開(kāi)卷有益(求醫(yī)問(wèn)藥);2002年11期

10 吳秀英;運(yùn)動(dòng)中的是非題[J];家庭醫(yī)學(xué);2002年09期

相關(guān)會(huì)議論文 前10條

1 陳福偉;楊國(guó)宇;李宏基;郭豫杰;魯維飛;;小鼠脂肪組織中孤啡肽及其受體基因表達(dá)的研究[A];全國(guó)動(dòng)物生理生化第十一次學(xué)術(shù)交流會(huì)論文摘要匯編[C];2010年

2 鄒曉防;;脂肪組織與創(chuàng)面愈合[A];第八屆全國(guó)燒傷外科學(xué)年會(huì)論文匯編[C];2007年

3 孫q，

本文編號(hào)：2183244